Voglibose is an inhibitor of α-glucosidase that exhibits anti-diabetic, anti-hyperglycemic, anti-hyperlipidemic, anti-melanogenic, and cardioprotective benefits. In obese mice, voglibose increases plasma levels of glucagon-like peptide 1 (GLP-1), indirectly decreasing activity of DPP4. Additionally, voglibose decreases expression of intracellular adhesion molecule 1 (ICAM-1) and excretion of C-reactive protein (CRP), also decreasing oxidative stress. In clinical studies, voglibose improves body mass index and hemoglobin A1c values and decreases hyperlipidemia and hyperglycemia. Inhibition of α-glucosidase also blocks N-glycan modification of tyrosinase, decreasing levels of tyrosinase and melanin. In several animal models of myocardial ischemia/reperfusion, voglibose upregulates phosphorylated Akt and phosphorylated eNOS expression, decreasing myocardial infarction size; this compound may also activate GLP-1 receptors or open mitochondrial K+ (ATP) channels.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.